Linganisha mbinu

	Kipimo cha Upenyezaji wa Seli za Caco-2	Utoaji wa Dawa kwa Njia ya Liposomal
Nyanja	Famakolojia	Famakolojia
Familia	Process / pipeline	Process / pipeline
Mwaka wa asili	1989	1965
Mwanzilishi	Ingrid Hidalgo	Alec Bangham
Aina	absorption screening	formulation technology
Chanzo asilia	Hidalgo, I. J., Raub, T. J., & Borchardt, R. T. (1989). Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology, 96(3), 736-749.	Bangham, A. D., Standish, M. M., & Watkins, J. C. (1965). Diffusion of univalent ions across the lamellae of swollen phospholipid films and the determination of membrane potential. Journal of Molecular Biology, 13(1), 238-252.
Majina mbadala	Caco-2 assay, intestinal permeability, ADME screening	liposomal formulation, vesicular delivery, lipid nanoparticles
Zinazohusiana	3	3
Muhtasari	The Caco-2 assay is an in vitro model system using human colon carcinoma cell monolayers to screen drug intestinal permeability. Developed by Hidalgo and colleagues in 1989, Caco-2 cells differentiate into an epithelial barrier resembling intestinal mucosa, enabling rapid assessment of drug absorption potential and identification of transporter-mediated transport.	Liposomal encapsulation is a formulation technique using lipid bilayer vesicles (liposomes) to enclose drugs, improving bioavailability, reducing toxicity, and enabling targeted delivery. Developed by Alec Bangham in 1965, liposomes are now standard in pharmaceutical development, with several FDA-approved liposomal drugs on the market.